SEC Form 4 · accession 0001209191-15-033552

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Apr 8, 2015

Accepted (ET)

Apr 10, 2015 · 4:10 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Apr 8, 2015	M	1,300	$17.16	A	387,584	D
Common Stock	Apr 8, 2015	M	10,400	$35.64	A	397,984	D
Common Stock^F2,F3	Apr 8, 2015	S	7,100	$123.06	D	390,884	D
Common Stock^F3,F4	Apr 8, 2015	S	4,600	$123.57	D	386,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock^F5	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F6	$17.16	Apr 8, 2015	M	1,300	D	—	Jul 19, 2015	Common Stock	1,300	18,700	D
Stock Option (right to buy)^F6	$35.64	Apr 8, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	437,600	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Open market sales reported on this line occurred at a weighted average price of $123.06 (range $122.35 to $123.34).
F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4Open market sales reported on this line occurred at a weighted average price of $123.57 (range $123.37 to $124.24).
F5Common stock held in grantor retained annuity trusts.
F6Fully vested.